Business Wire

CA-NETAPP,-INC.

10.7.2024 14:01:33 CEST | Business Wire | Press release

Share
NetApp Expands Intelligent Data Infrastructure Capabilities to Power Strategic Cloud Workloads

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the introduction of new capabilities designed for strategic cloud workloads including GenAI and VMware. These enhancements to NetApp data and storage services reduce the resources and risks for customers to manage these strategic workloads across increasingly complex hybrid multicloud environments.

“Strategic workloads, including GenAI and virtualized environments, are driving business innovation and have increasingly complex and resource-intensive infrastructure requirements that are pushing IT teams to the limit,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage at NetApp. “NetApp is helping customers take back control of their data with intelligent data infrastructure that leverages unified data storage, integrated data services, and automated cloud operations. Even when they are up against specific and nuanced technology requirements for modern workloads, NetApp gives them the tools they need to optimize and simplify their data operations in their environments across the hybrid multicloud.”

To advance intelligent data infrastructure deployments that better support strategic workloads like GenAI and VMware environments, NetApp is announcing new capabilities, including:

  • NetApp BlueXP Workload Factory – for AWS: This intelligent data infrastructure service uses defined industry best-practices to automate the planning, provisioning, and management of cloud resources and services for key workloads, including GenAI, VMware cloud environments, and enterprise databases. Customers can use BlueXP workload factory to optimize deployment time, cost, performance, and protection of resources for strategic workloads as well as their associated data. To simplify workload migrations to the cloud, BlueXP workload factory allows users to profile infrastructure requirements for target workloads and compare different resource options for cost and performance needs. Then, the service can provision the selected resources, move any existing workload data to these newly provisioned cloud deployments, and continually optimize the entire environment to ensure the required cost and performance targets. AWS users can read guidance on how to deploy this capability on the AWS Solutions Library.
  • NetApp GenAI Toolkit – Microsoft Azure NetApp Files Version: Customers can now include private enterprise data stored in Azure NetApp Files in their retrieval-augmented generation (RAG) workflows in a secure, programmatic manner. The result is an enhanced ability to generate unique, high-quality, and ultra-relevant results from GenAI projects by combining their proprietary data with pre-trained, foundational models (FMs). The integration of the NetApp GenAI Toolkit with Azure NetApp Files represents a powerful synergy that empowers customers to harness advanced language generation capabilities.
  • Amazon Bedrock with Amazon FSx for NetApp ONTAP Reference Architecture: Amazon Web Services, Inc. (AWS) and NetApp have released a joint reference architecture which provides guidance for customers on implementing RAG-enabled workflows that bring proprietary data stored on Amazon FSx for NetApp ONTAP into their GenAI data pipelines. Amazon FSx makes it easy and cost effective to launch, run, and scale feature-rich, high-performance file systems in the cloud. The reference architecture allows developers to use APIs for Amazon Bedrock to connect with Amazon FSx for ONTAP data stores, enabling the secure use of proprietary data with a choice of high-performing FMs that can be customized to unlock new insights and capabilities.
  • Amazon FSx for NetApp ONTAP Enhancements: AWS announced the next-generation Amazon FSx for ONTAP cloud storage service with enhanced capabilities to boost scalability and flexibility to provide up to 6 GB per second of throughput for a single highly-available (HA) pair from 512 TiB of SSD storage. Next-gen file systems offer virtualized workloads more room to grow with a 300 percent increase in network burst throughput and a 150 percent boost in disk burst throughput. For large-scale, high-performance workloads like GenAI, second-generation Amazon FSx for ONTAP systems support dynamic scalability by adding HA pairs as needed, up to 24 nodes. This delivers up to 72 GB per second of throughput from 1 PiB of SSD storage, providing greater flexibility and performance for evolving business needs.
  • NetApp BlueXP Disaster Recovery Support for VMFS: The BlueXP disaster recovery service, which provides guided workflows to design and execute automated disaster recovery plans for VMware workloads across both on-premises and cloud environments, has been expanded to support VMFS datastores for on-premises to on-premises disaster recovery.

These updates build on NetApp’s existing offerings that support storage and data operations for customers that need to implement and manage high-powered, strategic workloads such as GenAI and VMware environments. For example, NetApp recently announced that its unique BlueXP data classification capability, which automatically classifies and categorizes data for enhanced governance and secure ingest into GenAI and RAG data pipelines, has become a core control plane capability now available free of charge to all NetApp customers.

“When it comes to GenAI, the prime focus for organizations is to adapt their data strategies to ensure they can balance data security, cost efficiency and innovation as they leverage pre-built LLMs to surface relevant, useful insights from their proprietary, business-relevant data,” said Archana Venkatraman, Senior Research Director, Cloud Data Management at IDC. “NetApp’s intelligent data infrastructure capabilities can help customers overcome the data challenges and offer specific guidance to automate workflows that can securely feed private data directly into public cloud providers’ LLMs. In addition, NetApp’s BlueXP data classification capability has the potential to mitigate the risks in data operations for AI because it allows users to discover and categorize data so that the right data is fed into the right model without exposing confidential, personal or restricted information.”

“Organizations are now facing different economic realities with regards to virtualized environments, and we all need to move quickly to address recent industry shifts,” said Derek Elbert, Solutions Architect at WWT. “Optimizing the cost versus performance equation of VMware workloads has become a primary initiative for us, with the objective of continuing to provide scalability and performance while reducing unnecessary system and software resources. NetApp’s offerings, such as the BlueXP disaster recovery service and the optimization metrics from Cloud Insights, help us better ensure the right levels of resource allocation and protection schemes for virtual environments, allowing us to focus on putting our infrastructure to work without killing the FinOps metrics.”

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710415938/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye